Evidence map›Paper›PMID 38846063›Full record

ArticleJournal of diabetes research2024

Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database.

Matthew Anson, Ayesha Malik, Sizheng S Zhao, Philip Austin, Gema H Ibarburu, Shabbar Jaffar, Anupam Garrib, Daniel J Cuthbertson, Uazman Alam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Optimizing the right time to start sickle cell therapies.Hematology. American Society of Hematology. Education Program · 2025
    Review
  4. Comprehensive impact ofWorld journal of diabetes · 2025
    Article
  5. Review
  6. Protective Effects of Isolated Curcumin FromJournal of diabetes research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew AnsonDiabetes & Endocrinology Research and Pain Research Institute Institute of Life Course and Medical Sciences University of Liverpool and Liverpool University Hospital NHS Foundation Trust, LiverpoolUK.ORCID https://orcid.org/0000-0001-9991-7369
Ayesha MalikSchool of Medicine Barts and the London Queen Mary University of London, LondonUK.
Sizheng S ZhaoCentre for Musculoskeletal Research Division of Musculoskeletal and Dermatological Science School of Biological Sciences Faculty of Biological Medicine and Health The University of Manchester Manchester Academic Health Science Centre, ManchesterUK.ORCID https://orcid.org/0000-0002-3558-7353
Philip AustinTriNetX LLC, Cambridge, MassachusettsUSA.
Gema H IbarburuTriNetX LLC, Cambridge, MassachusettsUSA.
Shabbar JaffarUCL Institute for Global Health University College London, LondonUK.ORCID https://orcid.org/0000-0002-9615-1588
Anupam GarribUCL Institute for Global Health University College London, LondonUK.ORCID https://orcid.org/0000-0003-2305-3749
Daniel J CuthbertsonDiabetes & Endocrinology Research Institute of Life Course and Medical Sciences University of Liverpool and Liverpool University Hospital NHS Foundation Trust, LiverpoolUK.
Uazman AlamDiabetes & Endocrinology Research and Pain Research Institute Institute of Life Course and Medical Sciences University of Liverpool and Liverpool University Hospital NHS Foundation Trust, LiverpoolUK.ORCID https://orcid.org/0000-0002-3190-1122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Drug Therapy, CombinationGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinMetforminSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsAgedBlood GlucoseDatabases, FactualFemaleHumansMaleMiddle AgedPioglitazoneBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinMetforminPioglitazoneSodium-Glucose Transporter 2 InhibitorsSulfonylurea Compoundscardiovascular outcomesominous octetpioglitazonetype 2 diabetes

Identifiers

PMID38846063
PMCPMC11156508

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.